Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
16.81
-0.60 (-3.45%)
At close: Nov 14, 2025, 4:00 PM EST
16.93
+0.12 (0.71%)
After-hours: Nov 14, 2025, 4:04 PM EST
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $15.00K in the quarter ending September 30, 2025, a decrease of -55.88%. This brings the company's revenue in the last twelve months to $41.00K, down -34.92% year-over-year. In the year 2024, Lyell Immunopharma had annual revenue of $61.00K, down -53.08%.
Revenue (ttm)
$41.00K
Revenue Growth
-34.92%
P/S Ratio
7,932.82
Revenue / Employee
$137
Employees
300
Market Cap
325.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LYEL News
- 2 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire
- 5 days ago - Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer - GlobeNewsWire
- 12 days ago - Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewsWire
- 4 months ago - Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement - Seeking Alpha